1. Home
  2. AIM vs MDRR Comparison

AIM vs MDRR Comparison

Compare AIM & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIM
  • MDRR
  • Stock Information
  • Founded
  • AIM 1966
  • MDRR 2015
  • Country
  • AIM United States
  • MDRR United States
  • Employees
  • AIM N/A
  • MDRR N/A
  • Industry
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • MDRR Real Estate Investment Trusts
  • Sector
  • AIM Health Care
  • MDRR Real Estate
  • Exchange
  • AIM Nasdaq
  • MDRR Nasdaq
  • Market Cap
  • AIM 9.8M
  • MDRR 13.9M
  • IPO Year
  • AIM N/A
  • MDRR 2018
  • Fundamental
  • Price
  • AIM $0.13
  • MDRR $12.50
  • Analyst Decision
  • AIM Strong Buy
  • MDRR
  • Analyst Count
  • AIM 2
  • MDRR 0
  • Target Price
  • AIM $2.75
  • MDRR N/A
  • AVG Volume (30 Days)
  • AIM 1.4M
  • MDRR 6.2K
  • Earning Date
  • AIM 04-01-2025
  • MDRR 03-18-2025
  • Dividend Yield
  • AIM N/A
  • MDRR 1.72%
  • EPS Growth
  • AIM N/A
  • MDRR N/A
  • EPS
  • AIM N/A
  • MDRR 0.02
  • Revenue
  • AIM $190,000.00
  • MDRR $9,735,127.00
  • Revenue This Year
  • AIM N/A
  • MDRR N/A
  • Revenue Next Year
  • AIM $1,693.10
  • MDRR N/A
  • P/E Ratio
  • AIM N/A
  • MDRR $665.64
  • Revenue Growth
  • AIM N/A
  • MDRR N/A
  • 52 Week Low
  • AIM $0.11
  • MDRR $10.90
  • 52 Week High
  • AIM $0.62
  • MDRR $15.00
  • Technical
  • Relative Strength Index (RSI)
  • AIM 40.32
  • MDRR 47.35
  • Support Level
  • AIM $0.11
  • MDRR $12.37
  • Resistance Level
  • AIM $0.16
  • MDRR $12.80
  • Average True Range (ATR)
  • AIM 0.02
  • MDRR 0.55
  • MACD
  • AIM 0.00
  • MDRR -0.04
  • Stochastic Oscillator
  • AIM 32.00
  • MDRR 22.48

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified REIT Inc is engaged in the acquisition, reposition, renovation, leasing, and managing of income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its principal objectives include sourcing value-added Investments in markets in which it maintains deep industry relationships and local market knowledge and the creation of value for stockholders by utilizing its relationships and local knowledge of commercial real estate investment, management, and disposition.

Share on Social Networks: